We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+25.49%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$918M
AUM Growth
+$52.7M
Cap. Flow
-$46.8M
Cap. Flow %
-5.1%
Top 10 Hldgs %
48.26%
Holding
70
New
15
Increased
16
Reduced
21
Closed
16
Avg Time Held Equity + Options
0.5 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.4 years
Top 20 Avg Time Held Equity only
0.4 years

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$38.1M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$29.8M
3
AZN icon
AstraZeneca
AZN
+$18.5M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$18.5M
5
BIIB icon
Biogen
BIIB
+$13.9M

Top Sells

Rank Stock Value
1
AGN
Allergan plc
AGN
+$39.5M
2
HCA icon
HCA Healthcare
HCA
+$23.2M
3
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$20.9M
4
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$18.8M
5
WCG
Wellcare Health Plans, Inc.
WCG
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.78%
2 Miscellaneous 9.3%
3 Technology 2.51%
4 Communication Services 1.69%
5 Financials 0.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IHF icon
51
iShares US Healthcare Providers ETF
IHF
$1.44B
$296K 0.03%
12,500
-1,000
-7% -$22.5K
2014 Q3
1 quarter
ALXN
52
DELISTED
Alexion Pharmaceuticals
ALXN
$257K 0.03%
+1,390
New +$258K
2014 Q4
0 quarters
VIRX icon
53
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$64K 0.01%
+119
New +$53.6K
2014 Q4
0 quarters
AGIO icon
54
Agios Pharmaceuticals
AGIO
$1.93B
– –
-49,200
Closed -$3.02M –
ALGN icon
55
Align Technology
ALGN
$10.6B
– –
-172,772
Closed -$8.93M –
BMRN icon
56
BioMarin Pharmaceuticals
BMRN
$10.8B
– –
-177,079
Closed -$12.8M –
HCA icon
57
HCA Healthcare
HCA
$101B
– –
-328,292
Closed -$23.2M –
OEF icon
58
PUT
iShares S&P 100 ETF
OEF
$20.6B
– –
-450,000
Closed -$49.2M –
PRTA icon
59
Prothena Corp
PRTA
$436M
– –
-125,973
Closed -$2.79M –
ICPT
60
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-2,212
Closed -$524K –
CSII
61
DELISTED
Cardiovascular Systems, Inc.
CSII
– –
-370,208
Closed -$8.75M –
OTIC
62
DELISTED
Otonomy, Inc.
OTIC
– –
-18,400
Closed -$442K –
CLVS
63
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-100,000
Closed -$4.54M –
HMSY
64
DELISTED
HMS Holdings Corp.
HMSY
– –
-303,571
Closed -$5.72M –
MNK
65
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-231,389
Closed -$20.9M –
AGN
66
DELISTED
Allergan plc
AGN
– –
-163,898
Closed -$39.5M –
CYBX
67
DELISTED
CYBERONICS INC
CYBX
– –
-172,900
Closed -$8.85M –
KYTH
68
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
– –
-281,479
Closed -$9.22M –
CBST
69
DELISTED
CUBIST PHARMACEUTICALS INC
CBST
– –
-283,756
Closed -$18.8M –
1 2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2014 Portfolio in Review

As of Q4 2014, Redmile Group held 70 positions worth $918M, up 6.1% from $866M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group withdrew a net $46.8M in Q4 2014, closing 16 positions and reducing 21 holdings. Its most notable exit was Allergan plc, an estimated $39.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 76% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Redmile Group opened a new position in Gilead Sciences worth $34.7M.

  • Redmile Group's largest Q4 2014 buy was Gilead Sciences: 368,615 shares worth $34.7M.
  • Redmile Group added most to Seagen Inc. Common Stock in Q4 2014, an estimated $29.8M increase.
  • Redmile Group's biggest Q4 2014 reduction was Wellcare Health Plans, Inc., cutting an estimated $15.3M.
  • Redmile Group fully exited Allergan plc in Q4 2014, selling an estimated $39.5M.
  • Redmile Group's ten largest holdings make up 48% of its $918M portfolio in Q4 2014.
  • Redmile Group opened 15 new positions and closed 16 in Q4 2014.
  • Redmile Group's portfolio value rose 6.1% quarter-over-quarter to $918M.

Based on Redmile Group's 13F filing for Q4 2014, filed 18 Feb 2015.